280
Views
5
CrossRef citations to date
0
Altmetric
Review

Epoprostenol for the treatment of pulmonary arterial hypertension

, &
Pages 1005-1013 | Received 03 Mar 2021, Accepted 11 May 2021, Published online: 07 Jun 2021

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Josianne Gauthier, Dunavan Morris-Janzen & Alexander Poole. (2023) Iloprost for the treatment of frostbite: a scoping review. International Journal of Circumpolar Health 82:1.
Read now
Ralf Ewert, Dirk Habedank, Michael Halank, Beate Stubbe & Christian F. Opitz. (2022) Strategies for optimizing intravenous prostacyclin-analog therapy in patients with pulmonary arterial hypertension. Expert Review of Respiratory Medicine 16:1, pages 57-66.
Read now

Articles from other publishers (3)

Zuomei Zeng, Xinyue Wang, Lidan Cui, Hongjuan Wang, Jian Guo & Yucai Chen. (2023) Natural Products for the Treatment of Pulmonary Hypertension: Mechanism, Progress, and Future Opportunities. Current Issues in Molecular Biology 45:3, pages 2351-2371.
Crossref
Jiuliang Zhao, Qian Wang, Xiaoyue Deng, Junyan Qian, Zhuang Tian, Yongtai Liu, Mengtao Li & Xiaofeng Zeng. (2022) The treatment strategy of connective tissue disease associated pulmonary arterial hypertension: Evolving into the future. Pharmacology & Therapeutics 239, pages 108192.
Crossref
Ghina’a I. Abu Deiab & Mitchell P. Croatt. (2022) Prostacyclin (PGI2) scaffolds in medicinal chemistry: current and emerging drugs. Medicinal Chemistry Research 31:8, pages 1241-1251.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.